Depciuch Joanna, Sieminska Izabela, Jakubczyk Pawel, Klebowski Bartosz, Ptak Katarzyna, Szymońska Izabela, Kwinta Przemko, Siedlar Maciej, Kęsik Jan Jakub, Parlinska-Wojtan Magdalena, Baran Jarek
Institute of Nuclear Physics, Polish Academy of Sciences, Walerego Eljasza - Radzikowskiego 152, Kraków, 31-342, Poland.
Department of Biochemistry and Molecular Biology, Medical University of Lublin, Chodźki 1, Lublin, 20-093, Poland.
Sci Rep. 2025 Feb 7;15(1):4669. doi: 10.1038/s41598-025-88976-4.
Pediatric Inflammatory Multisystem Syndrome (PIMS-TS), associated with SARS-CoV-2 infection, is a severe complication after COVID-19 in children. It is caused by the immune reaction to SARS-CoV-2, and usually appears three to six weeks after the infection. Unfortunately, PIMS causes non-specific symptoms, which makes its diagnosis and treatment difficult. In this paper, we propose Fourier Transform InfraRed spectrometry (FTIR) to identify chemical changes in blood serum of children induced by PIMS and caused by subsequent treatment of the syndrome. The results suggest that although the Principal Component Analysis (PCA) of FTIR data did not allow for differentiation of healthy children and children with PIMS before and after the treatment, the implementation of Support Vector Machine (SVM) showed that the accuracy of the FTIR region between 800 cm and 1800 cm in PIMS detection is as high as 92% with a sensitivity of 100%. The difference in the chemical compositions of sera from the control group and the children after the treatment was detected in 54%, indicating that the treatment was effective. Indeed, the obtained medical data clearly showed a decrease of C-reactive protein (CRP) and Procalcitonin (PCT) concentration in serum after the treatment. The decision tree showed that peak 1455 cm could be used as a potential FTIR PIMS marker. Importantly, FTIR data correlates well with medical parameters, however the correlation differs with respect to the groups before and after the treatment.
儿童炎症性多系统综合征（PIMS-TS）与SARS-CoV-2感染相关，是儿童感染新冠病毒后的一种严重并发症。它由机体对SARS-CoV-2的免疫反应引起，通常在感染后三至六周出现。不幸的是，PIMS会引发非特异性症状，这使得其诊断和治疗都很困难。在本文中，我们提出使用傅里叶变换红外光谱法（FTIR）来识别由PIMS以及该综合征后续治疗所导致的儿童血清中的化学变化。结果表明，尽管FTIR数据的主成分分析（PCA）无法区分治疗前后健康儿童和患有PIMS的儿童，但支持向量机（SVM）的应用显示，在800厘米至1800厘米的FTIR区域进行PIMS检测时，准确率高达92%，灵敏度为100%。检测发现，对照组和治疗后儿童血清的化学成分差异率为54%，这表明治疗是有效的。事实上，所获得的医学数据清楚地显示，治疗后血清中C反应蛋白（CRP）和降钙素原（PCT）的浓度有所下降。决策树显示，1455厘米处的峰值可用作潜在的FTIR PIMS标志物。重要的是，FTIR数据与医学参数具有良好的相关性，不过治疗前后组别的相关性有所不同。
